Pfizer

Pfizer is about resilience and dividend yield

Valrodmon

Not Invested

Community Contributor

Published

31 Dec 25

Views

486

31 Dec

US$26.04

Valrodmon's Fair Value

US$28.00

7.0% undervalued

8.6%

1.6%

8.6%

1.6%

You can edit this narrative until Jan 1 2:50 AM. Then, changes will post as Updates.

Author's Valuation

US$287.0% undervalued

Valrodmon's Fair Value

Valuator

Company Info

Notes

Valrodmon'sFair Value

US$28

7.0% undervalued

Future estimation in

Revenue

Profit Margin

Future PE

Growth p.a.

Decrease

Increase

Forecast revenue growth rate

-3.63%

Historical revenue growth rate

-5.01%

Pharma revenue growth rate

0.53%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.11%

Calculation

US$15.61b

Earnings '30

14.50x

PE Ratio '30

US$226.45b

Market Cap '30

US$226.45b

Market Cap '30

5.78b

No. shares '30

US$39.19

Share Price '30

US$39.19 Share Price '30

Discounted to 2025 @ 6.96% p.a.

US$28.00

Fair Value '25